Literature DB >> 11906965

Anthrapyridones, a novel group of antitumour non-cross resistant anthraquinone analogues. Synthesis and molecular basis of the cytotoxic activity towards K562/DOX cells.

J Tarasiuk1, B Stefańska, I Plodzich, K Tkaczyk-Gobis, O Seksek, S Martelli, A Garnier-Suillerot, E Borowski.   

Abstract

1. Multidrug resistance (MDR) to antitumour agents, structurally dissimilar and having different intracellular targets, is the major problem in cancer therapy. MDR phenomenon is associated with the presence of membrane proteins which belong to the ATP-binding cassette family transporters responsible for the active drug efflux leading to the decreased intracellular accumulation. 2. The search of new compounds able to overcome MDR is of prime importance. 3. Recently we have synthesized a new family of anthrapyridone compounds. The series contained derivatives modified with appropriate hydrophobic or hydrophylic substituents at the side chain. 4. The interaction of these derivatives with erythroleukemia K562 sensitive and K562/DOX resistant (overexpressing P-glycoprotein) cell lines has been examined. The study was performed using a spectrofluorometric method which allows to continuously follow the uptake and efflux of fluorescent molecules by living cells. 5. It was demonstrated that the increase in the lipophilicity of anthrapyridones favoured the very fast cellular uptake exceeding the rate of P-gp dependent efflux out of the cell. For these derivatives, very high accumulation (the same for sensitive and resistant cells) was observed and the in vitro biological data confirmed that these compounds exhibited comparable cytotoxic activity towards sensitive and P-gp resistant cell line. In contrast, anthrapyridones modified with hydrophylic substituents exhibited relatively low kinetics of cellular uptake. 6. For these derivatives decreased accumulation in resistant cells was observed and the in vitro biological data demonstrated that they were much less active against P-gp resistant cells in comparison to sensitive cells. 7. We also studied, using confocal microscopy, the intracellular distribution of anthrapyridones in NIH-3T3 cells. Our data showed that these compounds were strongly accumulated in the nucleus and lysosomes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11906965      PMCID: PMC1573273          DOI: 10.1038/sj.bjp.0704611

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  35 in total

1.  Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones.

Authors:  T Tsuruo; H Iida-Saito; H Kawabata; T Oh-hara; H Hamada; T Utakoji
Journal:  Jpn J Cancer Res       Date:  1986-07

2.  Pirarubicin might partly circumvent the P-glycoprotein-mediated drug resistance of human breast cancer tissues.

Authors:  T Kubota; T Furukawa; H Tanino; S Oura; H Murata; S Yuasa; K Morita; J Ueno; R Kozakai; T Yano
Journal:  Anticancer Res       Date:  1998 Mar-Apr       Impact factor: 2.480

3.  The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake.

Authors:  S Mankhetkorn; A Garnier-Suillerot
Journal:  Eur J Pharmacol       Date:  1998-02-19       Impact factor: 4.432

4.  A cationic derivative of amphotericin B as a novel delivery system for antisense oligonucleotides.

Authors:  C Garcia-Chaumont; O Seksek; B Jolles; J Bolard
Journal:  Antisense Nucleic Acid Drug Dev       Date:  2000-06

5.  Transport of new non-cross-resistant antitumor compounds of the benzoperimidine family in multidrug resistant cells.

Authors:  K Tkaczyk-Gobis; J Tarasiuk; O Seksek; B Stefanska; E Borowski; A Garnier-Suillerot
Journal:  Eur J Pharmacol       Date:  2001-02-16       Impact factor: 4.432

6.  Design, synthesis, and in vitro activity of catamphiphilic reverters of multidrug resistance: discovery of a selective, highly efficacious chemosensitizer with potency in the nanomolar range.

Authors:  E Teodori; S Dei; P Quidu; R Budriesi; A Chiarini; A Garnier-Suillerot; F Gualtieri; D Manetti; M N Romanelli; S Scapecchi
Journal:  J Med Chem       Date:  1999-05-20       Impact factor: 7.446

7.  8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.

Authors:  B Stefańska; M Dzieduszycka; M M Bontemps-Gracz; E Borowski; S Martelli; R Supino; G Pratesi; M De Cesare; F Zunino; H Kuśnierczyk; C Radzikowski
Journal:  J Med Chem       Date:  1999-09-09       Impact factor: 7.446

8.  Novel multidrug resistance reversal agents.

Authors:  D Berger; R Citarella; M Dutia; L Greenberger; W Hallett; R Paul; D Powell
Journal:  J Med Chem       Date:  1999-06-17       Impact factor: 7.446

9.  Decreased drug accumulation without increased drug efflux in a novel MRP-overexpressing multidrug-resistant cell line.

Authors:  C L Gaj; I Anyanwutaku; Y H Chang; Y C Cheng
Journal:  Biochem Pharmacol       Date:  1998-04-15       Impact factor: 5.858

10.  Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents.

Authors:  C Pascaud; M Garrigos; S Orlowski
Journal:  Biochem J       Date:  1998-07-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.